ATS 2020 Advance Program

• describe the research priorities of each funding agency represented on the panel; • identify specific criteria required and mechanisms of funding from each agency on the panel; • identify a funding agency that is most closely aligned with the attendee’s interest and program of research. This session will introduce programs and research funding opportunities offered from various government and non-government agencies. Speakers will present current research priorities and mechanisms of funding available within their respective agency. Time will be provided for audience members to ask questions of the panel of speakers. Chairing: N.E. Bracken, ACNPC, MSN, Chicago, IL A.M. Russell, PhD, RN, ATSF, London, United Kingdom 12:15 Welcome and Introductions N.E. Bracken, ACNPC, MSN, Chicago, IL 12:20 American Lung Association M.F. Busk, MD, MPH, Indianapolis, IN 12:32 The Patient Centered Outcomes Research Institute (PCORI) S. Daugherty, PhD, MPH, Washington, DC 12:44 National Institute of Nursing Research K. Huss, PhD, Bethesda, MD 12:56 ATS Foundation E.M. Nebel, MA, New York, NY 1:08 Discussion and Closing Remarks A.M.Russell, PhD,RN, ATSF, London,UnitedKingdom VETERANS ADMINISTRATION L2 NEW VA PROGRAM IN PRECISION ONCOLOGY FOR LUNG CANCER CARE AND RESEARCH 12:15 p.m. - 1:15 p.m. Target Audience Those involved in care and/or research related to lung cancer; all ATS members based in the VA. Objectives At the conclusion of this session, the participant will be able to: • learn new findings related to the VA’s new Precision Oncology Program for Lung Cancer Care and Research, including new opportunities for research and for access to clinical trials for veterans with lung cancer; • learn new findings about precision oncology and evaluation of patients with advanced non-small cell lung cancer for appropriateness of treatment with targeted tyrosine kinase inhibitors and immune enhancing therapies; • apply for research support from the VA’s new Precision Oncology Program for lung cancer care and research. In 2016, the VA instituted a national precision oncology program for prostate cancer. Elements included establishing 10 VA centers of excellence, as well as standardized genomic sequencing of tumors, to identify targetable mutants, and of circulating tumor DNA, for screening. Networking across sites ensured consistent levels of care. Through partnering with philanthropy and industry, the VA has provided funding for research and clinical trials, emphasizing support for young investigators. Leadership of Veterans Health Administration now is beginning a similar program for precision oncology in lung cancer. The goal of this session is to provide information about this new program. Chairing: J.K. Brown, MD, San Francisco, CA K.A. Myrie, PhD, Washington, DC 12:15 VHA’s New Precision Oncology Program for Lung Cancer M.J. Kelley, MD, Durham, NC 12:45 Rationale and Opportunity for Combination Immunotherapy for Non-Small Cell Lung Cancer S.M. Dubinett, MD, Los Angeles, CA 1:05 Lung Cancer Screening in the VA J.K. Brown, MD, San Francisco, CA ATS 2020 • Philadelphia, PA 48 SUNDAY • MAY 17